Alpha 2.0
Login Register
» Articles » PMID: 8636245

Acromegaly: What Constitutes Optimal Therapy?

Overview
Journal J Clin Endocrinol Metab
Publisher Oxford University Press
Specialty Endocrinology
Date 1996 Feb 1
PMID 8636245
Citations 8
Authors
L A Frohman
Affiliations
Soon will be listed here.
Citing Articles

Early lung function abnormalities in acromegaly.

Benfante A, Ciresi A, Bellia M, Cannizzaro F, Bellia V, Giordano C Lung. 2015; 193(3):393-9.

PMID: 25757541 DOI: 10.1007/s00408-015-9710-1.

Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.

Gradiser M, Matovinovic M, Vrkljan M Croat Med J. 2007; 48(1):87-91.

PMID: 17309144 PMC: 2080491.

Acromegaly: are new tests needed?.

Spada A J Endocrinol Invest. 2003; 26(2):104-5.

PMID: 12739734 DOI: 10.1007/BF03345135.

PPAR-gamma receptor ligands: novel therapy for pituitary adenomas.

Heaney A, Fernando M, Melmed S J Clin Invest. 2003; 111(9):1381-8.

PMID: 12727930 PMC: 154441. DOI: 10.1172/JCI16575.

Medical management of growth hormone-secreting pituitary adenomas.

Racine M, Barkan A Pituitary. 2003; 5(2):67-76.

PMID: 12675503 DOI: 10.1023/a:1022356313153.